FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890161092> ?p ?o ?g. }

• W2890161092 endingPage "324" @default.
• W2890161092 startingPage "317" @default.
• W2890161092 abstract "Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study Kamesh Gupta,1 Pooja Rani,1 Anurag Rohatgi,1 Mukesh Verma,1 Shivani Handa,2 Keemi Dalal,1 Anand Jain1 1Department of Internal Medicine, Lady Hardinge Medical College, New Delhi, India; 2Department of Gastroenterology, Liver Associates of Texas, Houston, TX, USA Objective: To evaluate the effectiveness of noradrenaline for the treatment of hepatorenal syndrome (HRS).Background: HRS represents the development of renal failure in cirrhotic patients. The standard treatment for HRS is terlipressin, which, as opposed to noradrenaline, is more expensive and less accessible in most tertiary care centers.Patients and methods: Thirty consecutive patients with HRS type 1 received noradrenaline (1–4.0 mg/hour) and albumin for 14 days. The parameters recorded were: serum creatinine levels, creatinine clearance, mean arterial pressure (MAP), urine output, and serum sodium levels evaluated at baseline and on treatment days 1, 3, 7, and 14.Results: Most patients achieved serum creatinine levels <1.5 mg/dL and were considered responders (22/30, 73%), whereas eight patients (27%) were nonresponders. At baseline, responders and nonresponders differed only regarding initial bilirubin levels and international normalized ratio values. Treatment duration was 7.5±3.2 days. Responders experienced a significant (p<0.05) decrease in serum creatinine levels (from 3.26±0.48 to 1.28±0.14 mg/dL), as well as a significant increase (p<0.05) in creatinine clearance (from 21±4.1 to 67.7±12.1 mL/min), urine output (from 583±41.1 to 1163±105 mL/day), MAP (from 79.2±2.94 to 93.9±2.34 mmHg), and serum sodium levels (from 125±2.01 to 132.3±1.39 mEq/L). In nonresponders, the MAP increased, but serum creatinine levels also increased, reflecting a decrease in creatinine clearance and urine output, with no significant change in serum sodium levels over the duration of the treatment.Conclusion: In most patients, noradrenaline treatment induced systemic vasoconstriction resulting in HRS reversal, with acceptable safety, in agreement with previously reported outcomes of terlipressin treatment. Keywords: hepatorenal syndrome, vasoconstrictor drug, noradrenaline, CKD, hypovolemia" @default.
• W2890161092 created "2018-09-27" @default.
• W2890161092 creator A5001242347 @default.
• W2890161092 creator A5005532354 @default.
• W2890161092 creator A5006031907 @default.
• W2890161092 creator A5010309184 @default.
• W2890161092 creator A5032609659 @default.
• W2890161092 creator A5037105610 @default.
• W2890161092 creator A5047947428 @default.
• W2890161092 date "2018-09-01" @default.
• W2890161092 modified "2023-09-25" @default.
• W2890161092 title "Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study" @default.
• W2890161092 cites W1511829932 @default.
• W2890161092 cites W1514685658 @default.
• W2890161092 cites W1967589221 @default.
• W2890161092 cites W1977356230 @default.
• W2890161092 cites W1989492547 @default.
• W2890161092 cites W1990415750 @default.
• W2890161092 cites W1992177436 @default.
• W2890161092 cites W2011199481 @default.
• W2890161092 cites W2019820739 @default.
• W2890161092 cites W2032310250 @default.
• W2890161092 cites W2034093103 @default.
• W2890161092 cites W2035686295 @default.
• W2890161092 cites W2037148704 @default.
• W2890161092 cites W2043539888 @default.
• W2890161092 cites W2045376161 @default.
• W2890161092 cites W2045620941 @default.
• W2890161092 cites W2048143719 @default.
• W2890161092 cites W2051278614 @default.
• W2890161092 cites W2057793946 @default.
• W2890161092 cites W2068351869 @default.
• W2890161092 cites W2072646675 @default.
• W2890161092 cites W2074466817 @default.
• W2890161092 cites W2075594879 @default.
• W2890161092 cites W2078113157 @default.
• W2890161092 cites W2078908900 @default.
• W2890161092 cites W2079304328 @default.
• W2890161092 cites W2087450723 @default.
• W2890161092 cites W2102518742 @default.
• W2890161092 cites W2103472550 @default.
• W2890161092 cites W2104359367 @default.
• W2890161092 cites W2104802633 @default.
• W2890161092 cites W2120179295 @default.
• W2890161092 cites W2131903288 @default.
• W2890161092 cites W2132058135 @default.
• W2890161092 cites W2142836329 @default.
• W2890161092 cites W2155487694 @default.
• W2890161092 cites W2156403153 @default.
• W2890161092 cites W2166731571 @default.
• W2890161092 cites W2166775393 @default.
• W2890161092 cites W2171487023 @default.
• W2890161092 cites W2534956713 @default.
• W2890161092 cites W3782647 @default.
• W2890161092 cites W4255387568 @default.
• W2890161092 doi "https://doi.org/10.2147/ceg.s153858" @default.
• W2890161092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6151092" @default.
• W2890161092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30271187" @default.
• W2890161092 hasPublicationYear "2018" @default.
• W2890161092 type Work @default.
• W2890161092 sameAs 2890161092 @default.
• W2890161092 citedByCount "15" @default.
• W2890161092 countsByYear W28901610922019 @default.
• W2890161092 countsByYear W28901610922020 @default.
• W2890161092 countsByYear W28901610922021 @default.
• W2890161092 countsByYear W28901610922022 @default.
• W2890161092 countsByYear W28901610922023 @default.
• W2890161092 crossrefType "journal-article" @default.
• W2890161092 hasAuthorship W2890161092A5001242347 @default.
• W2890161092 hasAuthorship W2890161092A5005532354 @default.
• W2890161092 hasAuthorship W2890161092A5006031907 @default.
• W2890161092 hasAuthorship W2890161092A5010309184 @default.
• W2890161092 hasAuthorship W2890161092A5032609659 @default.
• W2890161092 hasAuthorship W2890161092A5037105610 @default.
• W2890161092 hasAuthorship W2890161092A5047947428 @default.
• W2890161092 hasBestOaLocation W28901610921 @default.
• W2890161092 hasConcept C126322002 @default.
• W2890161092 hasConcept C126894567 @default.
• W2890161092 hasConcept C159641895 @default.
• W2890161092 hasConcept C188816634 @default.
• W2890161092 hasConcept C2776988256 @default.
• W2890161092 hasConcept C2777214474 @default.
• W2890161092 hasConcept C2779393834 @default.
• W2890161092 hasConcept C2780306776 @default.
• W2890161092 hasConcept C71924100 @default.
• W2890161092 hasConcept C90924648 @default.
• W2890161092 hasConceptScore W2890161092C126322002 @default.
• W2890161092 hasConceptScore W2890161092C126894567 @default.
• W2890161092 hasConceptScore W2890161092C159641895 @default.
• W2890161092 hasConceptScore W2890161092C188816634 @default.
• W2890161092 hasConceptScore W2890161092C2776988256 @default.
• W2890161092 hasConceptScore W2890161092C2777214474 @default.
• W2890161092 hasConceptScore W2890161092C2779393834 @default.
• W2890161092 hasConceptScore W2890161092C2780306776 @default.
• W2890161092 hasConceptScore W2890161092C71924100 @default.
• W2890161092 hasConceptScore W2890161092C90924648 @default.
• W2890161092 hasLocation W28901610921 @default.
• W2890161092 hasLocation W28901610922 @default.

• next